Paolo Milani - Publications

Susceptibility and screening approaches in systemic amyloidosis: expert perspectives from the International Society of Amyloidosis (ISA).

Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

Published: September 04, 2026

Laboratory investigations to rule out AL amyloidosis: practical guidance for the cardiologist

Journal: Giornale italiano di cardiologia (2006)

Published: July 29, 2026

Rate of incident polyneuropathy in patients with transthyretin amyloid cardiomyopathy.

Journal: International journal of cardiology

Published: March 30, 2026

Executive summary of the European consensus report on the diagnosis and treatment of monoclonal gammopathy of renal significance.

Journal: Clinical kidney journal

Published: January 28, 2026

Predicting Early Mortality in Newly Diagnosed AL Amyloidosis: Development and Validation of the PACE Score for Daratumumab-Treated Patients.

Journal: American journal of hematology

Published: January 20, 2026

Multicenter cohort analysis of cardiac amyloidosis patients treated with heart transplant.

Journal: Revista espanola de cardiologia (English ed.)

Published: January 19, 2026

Unveiling the unseen: navigating heart involvement in amyloidosis with biomarkers beyond the horizons of imaging.

Journal: European heart journal. Imaging methods and practice

Published: January 03, 2026

Reply: Refining Free Light Chain Ratio in Systemic Amyloidosis.

Journal: JACC. CardioOncology

Published: December 17, 2025

New Validated Staging System for Light Chain (AL) Amyloidosis With Stage IIIC Defining Ultra-Poor Risk: AL International Staging System.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 07, 2025

Monitoring heart involvement in treated and untreated transthyretin amyloidosis.

Journal: Heart failure reviews

Published: October 15, 2025

Eligibility criteria for clinical trials in AL amyloidosis result in exclusion of nearly half of real-world patients.

Journal: HemaSphere

Published: October 13, 2025

Hepatic response criteria in light chain amyloidosis: a multicenter validation study.

Journal: Haematologica

Published: September 20, 2025